COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities

Bonnie Ky; Douglas L. Mann

doi:10.1016/j.jaccao.2020.04.002

COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities

Bonnie Ky
, Douglas L. Mann

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, we provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.

Original language	English
Pages (from-to)	254-269
Number of pages	16
Journal	JACC: CardioOncology
Volume	2
Issue number	2
DOIs	https://doi.org/10.1016/j.jaccao.2020.04.002
State	Published - Jun 2020

Keywords

ACE2
COVID-19
SARS-CoV-2
clinical trials
renin angiotensin system

Access to Document

10.1016/j.jaccao.2020.04.002

Cite this

@article{eaff3ad9b8214cf88a64c316e1bc99d7,

title = "COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities",

abstract = "The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, we provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.",

keywords = "ACE2, COVID-19, SARS-CoV-2, clinical trials, renin angiotensin system",

author = "Bonnie Ky and Mann, \{Douglas L.\}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = jun,

doi = "10.1016/j.jaccao.2020.04.002",

language = "English",

volume = "2",

pages = "254--269",

journal = "JACC: CardioOncology",

issn = "2666-0873",

number = "2",

}

TY - JOUR

T1 - COVID-19 Clinical Trials

T2 - A Primer for the Cardiovascular and Cardio-Oncology Communities

AU - Ky, Bonnie

AU - Mann, Douglas L.

PY - 2020/6

Y1 - 2020/6

N2 - The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, we provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.

AB - The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, we provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.

KW - ACE2

KW - COVID-19

KW - SARS-CoV-2

KW - clinical trials

KW - renin angiotensin system

UR - https://www.scopus.com/pages/publications/85087417832

U2 - 10.1016/j.jaccao.2020.04.002

DO - 10.1016/j.jaccao.2020.04.002

M3 - Review article

C2 - 32313885

AN - SCOPUS:85087417832

SN - 2666-0873

VL - 2

SP - 254

EP - 269

JO - JACC: CardioOncology

JF - JACC: CardioOncology

IS - 2

ER -

COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this